OpenLegislation

The Health Protection (Notification) (Amendment) Regulations 2025

S.I. 2025/291 · Made 5 March 2025

Original text. legislation.gov.uk does not revise statutory instruments, so later amendments are not shown here. Changes made to it are listed under each provision when known.

PUBLIC HEALTH, ENGLAND

Made 5th March 2025

Laid before Parliament 7th March 2025

Coming into force 6th April 2025

The Secretary of State makes these Regulations in exercise of the powers conferred by sections 45C(1), (2) and (3)(a), 45F(2)(a) and (b), and 45P(2) of the Public Health (Control of Disease) Act 1984f1.

In accordance with section 45Q(3) of that Act, the Secretary of State is of the opinion that these Regulations do not contain any provision made by virtue of section 45C(3)(c) of the Act which imposes or enables the imposition of a special restriction or requirement or any other restriction or requirement which has or would have a significant effect on a person’s rights.

Annotations to the whole text

Footnotes

f1

1984 c. 22; sections 45C, 45F, 45P and 45Q were inserted by section 129 of the Health and Social Care Act 2008 (c. 14).

Contents

  1. 1Citation, commencement, extent and application
  2. 2Amendment to the Health Protection (Notification) Regulations 2010
  3. 3Amendment of regulation 4
  4. 4Amendment of Schedule 1
  5. 5Amendment of Schedule 2
  6. Signature
  7. Explanatory note

1Citation, commencement, extent and application

(1)

These Regulations may be cited as the Health Protection (Notification) (Amendment) Regulations 2025.

(2)

These Regulations come into force on 6th April 2025.

(3)

These Regulations extend to England and Wales and apply in relation to England only.

2Amendment to the Health Protection (Notification) Regulations 2010

The Health Protection (Notification) Regulations 2010f1 are amended in accordance with regulations 3 to 5.

3Amendment of regulation 4

In regulation 4 (duty on the operators of diagnostic laboratories to notify the United Kingdom Health Security Agency of causative agents found in human samples and of SARS-CoV-2 or influenza virus tests processed)—

(a)

in the heading, after “SARS-CoV-2” insert “, respiratory syncytial virus”;

(b)

in paragraph (1A)(b), after “of” insert “respiratory syncytial virus or”;

(c)

in paragraph (2)(ba), after “SARS-CoV-2” insert “, respiratory syncytial virus”.

4Amendment of Schedule 1

In Schedule 1 (Notifiable Diseases), at the appropriate alphabetical place insert—

  • Acute flaccid paralysis or acute flaccid myelitis (AFP or AFM)

  • Chickenpox (varicella)

  • Congenital syphilis

  • Creutzfeldt-Jakob disease (CJD)

  • Disseminated gonococcal infection (DGI)

  • Influenza of zoonotic origin

  • Middle East respiratory syndrome coronavirus (MERS)

  • Neonatal herpes

5Amendment of Schedule 2

In Schedule 2 (Causative Agents), at the appropriate alphabetical place insert—

  • Candidozyma auris

  • Echinococcus spp

  • Middle East respiratory syndrome coronavirus (MERS-CoV)

  • Non-human influenza A subtypes

  • Norovirus

  • Respiratory syncytial virus (RSV)

  • Tick-borne encephalitis virus (TBEV)

  • Toxoplasma (congenital toxoplasmosis)

  • Trichinella spp

  • Yersinia spp

Signature

Signed by the authority of the Secretary of State for Health and Social Care

Ashley Dalton

Parliamentary Under-Secretary of State

Department of Health and Social Care

5th March 2025

Explanatory note

(This note is not part of the Regulations)

These Regulations amend the Health Protection (Notification) Regulations 2010 (“the Principal Regulations”).

Regulation 3 amends regulation 4 of the Principal Regulations to require diagnostic laboratories to notify the United Kingdom Health Security Agency of the results of the respiratory syncytial virus (RSV) tests which they process, including where the test result is indeterminate, negative or void.

Regulation 4 adds acute flaccid paralysis or acute flaccid myelitis (AFP or AFM), chickenpox (varicella), congenital syphilis, Creutzfeldt-Jakob disease (CJD), disseminated gonococcal infection (DGI), influenza of zoonotic origin, Middle East respiratory syndrome coronavirus (MERS) and neonatal herpes to the list of notifiable diseases in Schedule 1 to the Principal Regulations.

Regulation 5 adds candidozyma auris, echinococcus spp, Middle East respiratory syndrome coronavirus (MERS-CoV), non-human influenza A subtypes, norovirus, respiratory syncytial virus (RSV), tick-borne encephalitis virus (TBEV), toxoplasma (congenital toxoplasmosis), trichinella spp and yersinia spp to the list of causative agents in Schedule 2 to the Principal Regulations.

A full impact assessment of the effect that this instrument will have on the costs of business, the voluntary sector and the public sector is available from the Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU, which is available alongside this instrument on the legislation.gov.uk website.